Anti-Human DR3 Purified

Description: The JD3 monoclonal antibody reacts with human DR3, also known as Apo-3, WSL-1, TRAMP, LARD, DDR3, and TR3. DR3, a novel death receptor is expressed at low level by monocytes and granulocytes. Interaction of DR3 with its ligand activates NF-kappa B pathway and induces apoptosis. Initially, DR3 was thought to be a receptor for TWEAK, but further studies have shown that TWEAK could induce apoptosis via receptors distinct from DR3. JD3 has been reported for use in flow cytometric analysis.

References: Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, Kominami E, Okumura K, Yagita H. Multiple pathways of TWEAK-induced cell death. J Immunol. 2002 Jan 15;168(2):734-43.

Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med. 2000 Nov 6;192(9):1373-80.